Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous
Reed‐Sternberg cells in an inflammatory background. Patients are commonly diagnosed …

Brentuximab vedotin (SGN-35; Adcetris®) is an anti-CD30 antibody conjugated via a
protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E …

Background Preclinical studies suggest that Reed–Sternberg cells exploit the programmed
death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma …

Background High-dose therapy followed by autologous stem-cell transplantation is standard
of care for patients with relapsed or primary refractory Hodgkin's lymphoma. Roughly 50% of …

Purpose Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers
monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I …

Background Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most
common tumors expressing CD30. Previous attempts to target the CD30 antigen with …

In relapsed/refractory Hodgkin lymphoma (R/R HL), immunotherapies such as the anti-
programmed death-1 inhibitor pembrolizumab have demonstrated efficacy as monotherapy …

AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the
treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via …

Purpose: The antibody–drug conjugate (ADC) brentuximab vedotin comprises a CD30-
directed antibody covalently attached to the potent antimicrotubule agent monomethyl …

Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC)
and autologous peripheral blood stem cell transplant (auto-PBSCT) predicts progression …